Construction of a herpes simplex virus/varicella-zoster virus (HSV/VZV) thymidine kinase recombinant with the pathogenic potential of HSV and a drug sensitivity profile resembling that of VZV

References

1. Balan P., Davis-Poynter N., Bell S., Atkinson H., Browne H., Minson T. 1994; An analysis of the in vitro and in vivo phenotypes of mutants of herpes simplex virus type 1 lacking glycoproteins gG, gE, gl or the putative gJ. Journal of General Virology 75:1245–1258
   [Google Scholar]
2. Bevilacqua F., Marcello A., Toni M., Zavattoni M., Cusini M., Zerboni R., Gerna G., Palu G. 1991; Acyclovir resistance/ susceptibility in herpes simplex vims type 2 sequential isolates from an AIDS patient. Journal of Acquired Immune Deficiency Syndrome 4:967–969
   [Google Scholar]
3. Biron K. K., Elion G. B. 1980; In vitro susceptibility of varicella-zoster virus to acyclovir. Antimicrobial Agents and Chemotherapy 18:443–447
   [Google Scholar]
4. Chen C., Okayama H. 1987; High-efficiency transformation of mammalian cells by plasmid DNA. Molecular and Cellular Biology 7:2745–2752
   [Google Scholar]
5. Collins P., Appleyard G. A., Oliver N. M. 1982; Sensitivity of herpes simplex virus isolates from acyclovir clinical trials. American Journal of Medicine 73:380–382
   [Google Scholar]
6. Darby G. 1993; The acyclovir legacy: its contribution to antiviral drug discovery. Journal of Medical Virology (Suppl.) 1:134–138
   [Google Scholar]
7. Davison A. J., Scott J. E. 1986; The complete DNA sequence of varicella zoster virus. Journal of General Virology 67:1759–1816
   [Google Scholar]
8. Dumas A. M., Geelen J. L. M. C., Weststrate M. W., Wertheim P., Van Der Noorda J. 1981; Xbal, Pstl, and Bgl II restriction enzyme maps of the two orientations of the varicella zoster genome. Journal of Virology 39:390–400
   [Google Scholar]
9. Efstathiou S., Kemp S., Darby G., Minson A. C. 1989; The role of herpes simplex virus type 1 thymidine kinase in pathogenesis. Journal of General Virology 70:869–879
   [Google Scholar]
10. Field A. K., Davis M. E., De Witt C., Perry H. C., Liou R., Germershausen J., Karkas J. D., Ashton W. T., Johnston D. B. R., Tolman R. L. 1983; 9-[2-hydroxy-1-(hydroxymethyl)-ethoxymethyl]guamne: a selective inhibitor of herpes group virus replication. Proceedings of the National Academy of Sciences, USA 80:4139–1143
    [Google Scholar]
11. Forrester A., Farrell H., Wilkinson G., Kaye J., Davis-Poynter N., Minson T. 1992; Construction and properties of a mutant of herpes simplex virus type 1 with glycoprotein H coding sequences deleted. Journal of Virology 66:341–348
    [Google Scholar]
12. Goodart S. A., Guzowsky J. F., Rice M. K., Wagner E. K. 1992; Effect of genomic location on expression of β-galactosidase mRNA controlled by the herpes simplex virus type 1 U_L 38 promoter. Journal of Virology 66:2973–2981
    [Google Scholar]
13. Haarr L., Marsden H. S., Preston C. M., Smiley J. R., Summers W. C., Summers W. P. 1985; Utilization of internal AUG codons for initiation of protein synthesis directed by mRNAs from normal and mutant genes encoding herpes simplex virus-specified thymidine kinase. Journal of Virology 56:512–519
    [Google Scholar]
14. Hill T. J., Field H. J., Blyth W. A. 1975; Acute and recurrent infection with herpes simplex virus in the mouse: a model for studying latency and recurrent disease. Journal of General Virology 28:341–353
    [Google Scholar]
15. Jacobson J. G., Martin S. L., Coen D. M. 1989; A conserved open reading frame that overlaps the herpes simplex virus thymidine kinase gene is important for viral growth in cell culture. Journal of Virology 63:1839–1843
    [Google Scholar]
16. Lacey S. F., Suzutani T., Powell K. L., Purifoy D. J. M., Honess R. W. 1991; Analysis of mutations in the thymidine kinase genes of drug-resistant varicella-zoster virus population using the polymerase chain reaction. Journal of General Virology 72:623–630
    [Google Scholar]
17. McGeoch D. J., Dolan A., Donald S., Rixon F. J. 1985; Sequence determination and genetic content of the short unique region in the genome of herpes simplex virus type 1. Journal of Molecular Biology 181:1–13
    [Google Scholar]
18. Munyon W., Kraiselburd E., Davis S., Mann J. 1971; Transfer of thymidine kinase to thymidine kinaseless L-cells by infection with ultraviolet irradiated herpes simplex virus. Journal of Virology 7:813–820
    [Google Scholar]
19. Myers M. G., Duer H. L., Hausler C. K. 1980; Experimental varicella-zoster virus infection of guinea pigs. Journal of Infectious Diseases 142:414–420
    [Google Scholar]
20. Myers M. G., Connelly B. L., Stanberry L. R. 1991; Varicella in hairless guinea pigs. Journal of Infectious Diseases 163:746–751
    [Google Scholar]
21. Purifoy D. J. M., Beauchamp L. M., de Miranda P., Ertl P., Lacey S., Roberts G., Rahim S. G., Darby G., Krenitsky T. A., Powell K. L. 1993; Review of research leading to new antiherpesvirus agents in clinical development: valaciclovir hydrochloride (256U, the L-valyl ester of acyclovir), and 882C, a specific agent for varicella-zoster virus. Journal of Medical Virology (Suppl.) 1:139–145
    [Google Scholar]
22. Rahim S. G., Trevidi N., Selway J., Darby G., Collins P., Powell K. L., Purifoy D. J. M. 1992; 5-Alkynyl pyrimidine nucleosides as potent selective inhibitors of varicella-zoster virus. Antiviral Chemistry and Chemotherapy 3:293–297
    [Google Scholar]
23. Roberts G. B., Fyfe J. A., McKee S. A., Rahim S. G., Daluge S. M., Almond M. R., Rideout J. L., Koszalka G. W., Krenitsky T. A. 1993; Varicella-zoster virus thymidine kinase: characterization and substrate specificity. Biochemical Pharmacology 46:2209–2218
    [Google Scholar]
24. Roemer K., Johnson P. A., Friedmann T. 1991; Activity of the simian 40 early promoter-enhancer in herpes simplex virus type 1 vectors is dependent on its position, the infected cell type and the presence of Vmwl75. Journal of Virology 65:6900–6912
    [Google Scholar]
25. Saiki R. K., Gelfand D. H., Stoffel S., Scharf S. J., Higuch R., Horn G. T., Mullis K. B., Erlich H. A. 1988; Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239:487–488
    [Google Scholar]
26. Sanger F., Nicklen S., Coulson A. R. 1977; DNA sequencing with chain-terminating inhibitors. Proceedings of the National Academy of Sciences, USA 74:5463–5467
    [Google Scholar]
27. Simmons A., Nash A. A. 1984; Zosteriform spread of herpes simplex virus as a model of recrudescence and its use to investigate the role of immune cells in prevention of recurrent disease. Journal of Virology 52:816–821
    [Google Scholar]
28. Smee D. F., Martin J. C., Verheyden J. P. H., Matthews T. R. 1983; Anti-herpes activity of the acyclic nucleoside 9-(1, 3-di-hydroxy-2-propoxymethyl)guanine. Antimicrobial Agents and Chemotherapy 23:676–682
    [Google Scholar]
29. Soike K., Huang J. L., Tu J. D., Stouffer B., Mitroka J. G., Swerdel M., Olsen S., Bonner D. P., Tuomari A. V., Fiel A. K. 1992; Oral bioavailability and anti-simian varicella virus efficacy of l-β-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) in monkeys. Journal of Infectious Diseases 165:732–736
    [Google Scholar]
30. Speck P. G., Simmons A. 1991; Divergent molecular pathways of productive and latent infection with a virulent strain of herpes simplex virus type 1. Journal of Virology 65:4001–1005
    [Google Scholar]
31. Summers W. P., Wagner M., Summers W. C. 1975; Possible peptide chain termination mutants in the thymidine kinase gene of a mammalian virus, herpes simplex virus. Proceedings of the National Academy of Sciences, USA 72:4081–4084
    [Google Scholar]
32. Tenser R. B., Jones J. C., Ressel S. J., Fralish F. A. 1983; Thymidine plaque autoradiography of thymidine kinase-positive and thymidine kinase-negative herpesviruses. Journal of Clinical Microbiology 17:122–127
    [Google Scholar]
33. Weber P. C., Levine M., Glorioso J. C. 1987; Rapid identification of nonessential genes of herpes simplex virus type 1 by Tn5 mutagenesis. Science 236:576–579
    [Google Scholar]
34. Yokota T., Konno K., Mori S., Shigeta S., Kumagai M., Watanabe Y., Machida H. 1989; Mechanism of selective inhibition of varicella zoster virus replication by 1-β-D-arabino-furanosyl-E-5-(2-bromovinyl)uracil. Molecular Pharmacology 36:312–316
    [Google Scholar]